Skip to main content

Advertisement

Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Fig. 4

STAT3 phosphorylation post IL-6 and gemcitabine treatment. Pancreatic cell lines MiaPaCa2 (a) and Panc01 (b) or healthy donor derived monocytes from donor 1 (c) or donor 2 (d) were cultured ±IL-6 (10 ng/ml) and/or ±gemcitabine (20 μM) and analyzed for STAT3 phosphorylation using Bio-plex Pro p-STAT3 (Tyr705) kit. Samples were run in triplicates. Statistical differences were calculated using one-way ANOVA multicomparison test at a 95 % confidence interval. Significant differences are labeled with an asterisk

Back to article page